Legend Biotech Corp (LEGN US): Carvykti Approval Is the Silver Lining Amid Uncertainty of Delisting
FDA approval of the company’s first drug Carvykti, with initial peak sales opportunity of $1.5 billion should be considered as a buy opportunity,...
Meihua International Medical Technologies Pre-IPO: Risks Overshadow Cheap Valuation
Meihua plans to raise $50 million by offering 5 million shares. At midpoint, the company would command a market cap of $250 million. Shares are...
Connect Biopharma IPO: Potent Medicine
Connect has launched a Nasdaq IPO to raise net proceeds of $135m at the mid-point of the IPO price range. Overall, we believe that the prospects of...
No more insights